MedTrace Logo

Blood Markers of Early Pancreas Cancer

NCT03568630 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1250

Last updated 2026-02-02

No results posted yet for this study

Summary

Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease.

The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.

Conditions

  • Diabetes Mellitus, Type 2
  • PreDiabetes
  • Pancreas Cyst
  • Chronic Pancreatitis
  • Genetic Predisposition to Disease
  • Inherited Disease

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Virginia Mason Hospital/Medical Center

    collaborator OTHER

  • VA Nebraska Western Iowa Health Care System

    collaborator FED

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Kelsey A Klute, MD · University of Nebraska

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-26
Primary Completion
2028-07-31
Completion
2028-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03568630 on ClinicalTrials.gov